Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

CLEVELAND, May 19, 2025 (GLOBE NEWSWIRE) -- NovelMed is pleased to announce positive 12-week interim results from the ongoing multi-dose Phase II trial of Ruxoprubart, a novel complement-targeting ...

The classical/lectin complement pathway is activated in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), as evidenced ... between subtypes of ANCA suggest distinct underlying ...

Some patients with ANCA-associated vasculitis exhibit a dominant anti-MPO response ... These results provide compelling evidence that mechanisms of dysregulated B-cell tolerance underlie AAV. The ...

ANCA Vasculitis Market Outlook 2025-2035 ... This evolution is driven by an enhanced understanding of the disease’s complex immune mechanisms and inflammatory pathways. Innovative treatments, such as ...

Owing to differences in mechanism, WGET does not completely ... treatment of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis. Takayasu's arteritis is a large vessel ...

A majority of patients with ANCA-associated vasculitis had coronary artery calcium on CT scans ... Future studies are warranted to delineate relative contributions of proposed mechanisms of ...

Substantial leaps forward in the ability to diagnose, treat, and monitor ANCA-associated vasculitis, however, will require breakthroughs in understanding disease biology. Efforts to illuminate the ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, ANCA Vasculitis pipeline constitutes 12+ key companies continuously working towards developing 12+ ANCA Vasculitis ...

The Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) drugs in development market research report provides comprehensive information on the therapeutics under development ...